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Introduction
Venous thromboembolism is a major cause of morbidity
and mortality with an incidence of about 1 per 1000 per
year [1]. Predisposing factors can be either genetic or
acquired. Acquired risk factors are surgery,
immobilisation, malignancy, oral contraceptives,
pregnancy and puerperium [2].
Until 1993, a specific genetic defect could be
identified in only 10-15% of affected subjects [3]. These
defects included deficiencies of protein C, protein S and
antithrombin [4], Protein C is an important inhibitor of
the clotting system, which mactivates cofactors Va and
Villa [5, 6]. Both these cofactors accelerate the
production of thrombin which converts soluble
fibnnogen into insolublefibrin.
Inherited resistance to activated protein C (APC
resistance), first descnbed in 1993 by Dahlbäck [7] (see
article by A. Hillarp and B. Dahlbäck, Vessels, this
issue), is the result of an abnormal factor V molecule,
(FVR506Q, FV Leiden) which turned out to be the most
common known cause of inherited thrombophilia [8-12].
Molecular genetics of Factor V Leiden
APC resistance is strongly associated with a single point
mutation (1,691 G->-A transition) in exon 10 of the factor
V gene (mapped to chromosome 1 (1q21-25)). This
mutation predicts the replacement of Arg-506 (CGA) by
Gin (CAA) in the factor V molecule which results in
FVR506Q or pv Lejden (Rg -,)
 Νοη713||Υι Arg-506-Gly-507
is one of the cleavage sites for APC, so replacement of
Arg-506 results in an inadequate inactivation by APC
(APC resistance) of the mutated Factor V molecule
which causes an increased tendency to develop
thrombosis [12]. This explains APC resistance in vitro,
for the activated thromboplastin time (APTT) is affected
by factor Va and the rate of its inactivation by APC.
When APC is added to plasma, it leads to a
Prolongation of the APTT. In the presence of mutated
factor V, this Prolongation of the APTT after
administration of APC is much reduced [7]. This is
expressed äs the APC sensitivity ratio, i.e. the ratio of
the APTTs before and after APC being added to the
plasma.
Inherited APC resistance is an autosomal dominant
trait [9, 10], This implies that on average, 50% of the
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Fig. 1: Model of factor Va and factor Va"5060, both composed of a heavy and a light chain. Cleavage at R506 will not occur in
FVa"5060 which results in a reduced inact/vation of the molecule APC = activated protein C.
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sibiings, children and parents of a heterozygous carrier
of FV Leiden also carry the mutation, and will be APC
resistant.
about 3% in unselected consecutive patients and
10-15% in selected symptomatic individuals from
thrombophilia families [15-17]
Epidemiology of Factor V Leiden
In a case-control study of 474 unselected consecutive
patients with a first deep venous thrombosis (Leiden
Thrombophilia Study, LETS), 14 of the 474 healthy
controls (3%) were heterozygous carriers of the FV
Leiden mutation. This is about ten times the prevalence
of protein C deficiency, protein S deficiency and
antithrombin deficiency combined. Others have
reported prevalences among healthy individuals
ranging between 0 and 15%. This wide ränge can be
explained to some extent by the mode of selection, but
there can be little doubt that there are true racial and
probably regional differences. The highest prevalence
has been found in Caucasians in Europe and Northern
America and the Iowest in Asia and Africa [13]. Within
Europe, higher prevalences have been reported in
Northern Europe than in Southern Europe with the
exception of some clusters of FV Leiden in Greek
Cypriots and Alsatians [14] (13.3% and 9.6%,
respectively, of healthy controls) (Table l)
Among patients with venous thrombosis, the
estimated prevalence of FV Leiden ranges from 20% of
unselected patients from the LETS study to 50% of
selected symptomatic individuals from families referred
because of unexplained familial thrombophilia [9, 10].
Again, this far exceeds the prevalence of the other
forms of inherited thrombophilia in patients with venous
thrombosis. The prevalence of (heterozygous)
deficiencies of protein C, protein S and antithrombin is
Risk of venous thrombosis
The LETS case-control study, and other studies have
demonstrated that, äs for protein C deficiency,
heterozygous carriers of FV Leiden mutation have a
seven- to 10-fold mcreased risk of venous thrombosis.
The risk of thrombosis for homozygous carriers is
increased by about 100-fold compared with non-carriers
(Table II) [18]. Ridker et al. performed a cohort study
and found an overall risk ratio of 2.7, which, after
restriction to individuals of 60 years and older,
increased to 7.0 [19].
Several studies demonstrate that the probability of
being free of venous thrombosis in thrombophilia-
families with FV Leiden was significantly reduced in
carriers. At the age of 50 years, about 25% of the
carriers had experienced at least one thrombotic event
(compared with about 5% for 50-year-old non-carriers
(Fig. 2)) [10, 20], Higher risks were found in
thrombophilia families with protein C deficiency; these
families however, were included by more selective
inclusion criteria [21].
This Variation in prevalence and risk demonstrates
the role of the selection of individuals. Many studies
have been performed using different inclusion criteria
(e.g. patients with a young age of onset, with
experience of recurrences, with thrombotic events in the
absence of main risk factors, with a positive family
history, unselected consecutive patients etc.) yielding
different kinds of Information. We recently compared the
Table I: Prevalence of FV"5060 among healthy'individuals.
Region Prevalence of FVn506Q among
healthy individuals (%)
Africa
Asia
Brazil
Northern Europe
Southern Europe
USA
0
0-1.1
2.0
3.4-7 9
0.6-2.9
6.0-7.6
Table II: FV"soe° and protein C deficiency in unselected
patients and controls [16,18, 22, 35].
Relative risk
Prevalence in controls
Prevalence in patients
Age of onset (years)
Protein C deficiency
>7.0
0.4%
3%
47
pyRSoeo
>7.0
5%
20%
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F/g. 2: Thrombosis-free survival in people with activated
protein C (APC) resistance and normal relatives. Differences
between affected and non-affected individuals were highly
significant. (Reprinted with permission; NEJM 1994, 330:
517-22.).
thrombotic tendency of FV Leiden and protein C
deficiency - defined äs the median age of the first
thrombotic event - in unselected patients from the LETS
study and in selected family members of patients who
were referred for thrombophilia work-up (Fig. 3). The
median age at the first thrombosis in the unselected
symptomatic carriers of FV Leiden from the LETS study
was 43 years (ränge 16-69 years) and for unselected
protein C deficient patients 47 years (ränge 19-63
years). In thrombophilia families the median age of
onset for selected symptomatic relatives (no probandi)
with FV Leiden was 29 years (ränge 15-74 years), and
for selected symptomatic relatives with protein C
deficiency 35 years (ränge 17-67 years) [22]. This
suggests that the overall thrombotic risk is similar in
carriers of FV Leiden and carriers of protein C
deficiency and that the median age of onset mainly
depends on the way patients are identified.
Combinations of gene defects, such äs FV Leiden
and protein C deficiency, FV Leiden and protein S
deficiency or FV Leiden and antithrombin deficiency,
each result in a higher risk than for the single defect. In
families in which protein C deficiency and FV Leiden
cosegregated, the lifetime risk of thrombosis was 31%
for carriers of only protein C deficiency, 13% for carriers
of only FV Leiden and 73% for those with the combined
defect [23]. In families with cosegregation of protein S
deficiency and FV Leiden, the lifetime risk of thrombosis
was 19% for carriers of only protein S deficiency, 19%
for carriers of only FV Leiden and 72% for those with
both defects [24]. Another study confirmed the high risk
for this combined defect [25]. In families in which
antithrombin deficiency cosegregated with FV Leiden,
lifetime risk of thrombosis was 50% for carriers of only
antithrombin deficiency, 20% for carriers of only FV
Leiden and 92% for those with both defects [26].
A synergistic gene-environmental effect has been
demonstrated for carrying FV Leiden and the use of oral
contraceptives. Within the LETS study, 155 premeno-
pausal female cases and 169 premenopausal female
controls were investigated. The risk of venous
thrombosis for users of oral contraceptives was
increased four-fold while this risk among carriers of FV
Leiden was increased eight-fold. Compared with non-
affected non-users, the relative risk of venous
thrombosis in carriers of FV Leiden who used oral
contraceptives was increased 30-fold (relative risk: 34.7;
95% C.I., 7.8-154) [27]. This synergistic effect stood out
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F/g. 3: Boxplot of age at the first venous thrombotic event
according to genetic defect in the four main groups. It shows
the ränge (horizontal lines at the end of the boxes) and median
age of onset (horizontal lines inside the boxes). The upper and
Iower boundaries are the 25th and 75th percentiles. Individuals
with combined defects were excluded
A: unselected patients from the LETS case-control study with
pif RS06Q
B: unselected patients from the LETS case-control study with
protein C deficiency.
C: selected patients from thrombophilia families with p|/B5ajo
D: selected patients from thrombophilia families with protein
C deficiency
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most clearly for so-called third generation oral
contraceptives - those contaming the progestogens
desogestrel and gestodene [28]
Arterial thrombosis
Some studies have demonstrated an association
between the presence of FV Leiden and coronary heart
disease [29], though others have failed to show this
[30] This mconsistency may be the result of different
modes of selection of patients Regarding the high
prevalence of the FV Leiden mutation and the high
prevalence of artenal thrombosis, it is important to
assess a possible association between the two In 1994,
Holm et al showed an association of myocardial
infarction and homozygosity of FV Leiden m two young
women [31] In a population-based case-control study
in Seattle, 472 women (84 cases with a first myocardial
infarction and 388 controls) were tested for the
presence of FV Leiden When adjusted for major
myocardial nsk factors FV Leiden lead to a four-fold
increased nsk of myocardial infarction (95% C l ,
1 2-121) [32] This suggests that FV Leiden is a nsk
factor for artenal disease m young women but not in
(older) men
Pregnancy and foetal loss
FV Leiden strongly increases the nsk of venous
thrombosis in pregnancy In one study, 60% of women
with thrombosis in pregnancy carned the FV Leiden
mutation [33] Carners of FV Leiden have an increased
nsk of foetal loss (miscarnage or stillbirth) Preston et al
demonstrated that the nsk for stillbirth m pregnant
carners of FV Leiden was increased two-fold (95% C l ,
0 5-7 7) (the odds ratio for miscarnages m carners was
0 9, 95% C l , 0 5 -1 5) [34]
Conclusion
Given the high prevalence of FV Leiden among healthy
individuals (-5%) it is unlikely that APC resistance in
itself is sufficient to cause thrombosis [35] Important to
clmicians is the question of which prophylactic and
diagnostic measures are advisable for patients with FV
Leiden and their relatives, especially when they are
exposed to other major nsk factors such äs surgery,
immobihsation, pregnancy or use of oral contraceptives
Unfortunately very few data are available on which to
base such guidelmes [17] Most centres will avoid
lifelong treatment with oral anticoagulants for
asymptomatic carners Treatment with anticoagulants
after a first venous thrombosis will usually be temporary
but duration of this treatment may also depend on the
seventy of the thrombotic event, positive family history
and other mdividual factors In general, recurrence of a
thrombotic event will result in lifelong therapy with
anticoagulants Surgery and immobilisation will, of
course require adequate anticoagulant prophylaxis
Before APC resistance was described by Dahlback
m 1993, few patients were diagnosed with hereditary
thrombophilia Considering the fact that the prevalence
of FV Leiden is at least 10-fold higher than the
prevalence of other known genetic deficiencies
together, this affects many patients and new studies are
needed to arrive at a rational clmical management
policy for these patients
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